$PALI
PALISADE BIO, INC.

2023 Q1 Form 10-K Financial Statement

#000095017023009226 Filed on March 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $250.0K $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.538M $1.505M $8.764M
YoY Change -47.49% -53.36% -5.83%
% of Gross Profit
Research & Development $1.241M $2.343M $6.547M
YoY Change 29.41% 192.88% 169.42%
% of Gross Profit
Depreciation & Amortization $1.000K $2.000K $3.000K
YoY Change 0.0% 50.0%
% of Gross Profit
Operating Expenses $2.779M $3.848M $15.72M
YoY Change -28.52% -4.44% -62.44%
Operating Profit -$2.529M -$15.72M
YoY Change -34.95% -62.44%
Interest Expense $0.00 $20.00K $13.00K
YoY Change -100.0% -99.61% -99.46%
% of Operating Profit
Other Income/Expense, Net $189.0K $108.0K $1.461M
YoY Change -159.62% 881.82% -90.41%
Pretax Income -$2.340M -$3.720M -$14.26M
YoY Change -44.35% -446.69% -46.42%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.340M -$3.720M -$14.26M
YoY Change -44.35% -446.69% -46.42%
Net Earnings / Revenue -936.0%
Basic Earnings Per Share -$0.54 -$16.53
Diluted Earnings Per Share -$0.54 -$2.06 -$16.53
COMMON SHARES
Basic Shares Outstanding 4.504M 77.08M 880.3K
Diluted Shares Outstanding 4.316M 880.3K

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.30M $12.38M $12.38M
YoY Change 100.14% 17.99% 17.99%
Cash & Equivalents $13.30M $12.40M $12.38M
Short-Term Investments
Other Short-Term Assets $684.0K $912.0K $912.0K
YoY Change -55.24% -51.46% -47.25%
Inventory
Prepaid Expenses
Receivables $300.0K $0.00
Other Receivables $78.00K
Total Short-Term Assets $14.31M $14.73M $14.73M
YoY Change 73.27% 19.06% 19.06%
LONG-TERM ASSETS
Property, Plant & Equipment $9.000K $10.00K $310.0K
YoY Change 350.0% 233.33% 176.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $643.0K $694.0K $720.0K
YoY Change 2373.08% 2569.23% 2669.23%
Total Long-Term Assets $953.0K $1.030M $1.030M
YoY Change 935.87% 646.38% 646.38%
TOTAL ASSETS
Total Short-Term Assets $14.31M $14.73M $14.73M
Total Long-Term Assets $953.0K $1.030M $1.030M
Total Assets $15.26M $15.76M $15.76M
YoY Change 82.78% 25.98% 25.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $706.0K $1.759M $1.759M
YoY Change -38.45% 32.96% 32.96%
Accrued Expenses $309.0K $574.0K $1.165M
YoY Change -46.72% 23.97% 7.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $88.00K $88.00K
YoY Change 1.15% 1.15%
Total Short-Term Liabilities $1.315M $3.012M $3.012M
YoY Change -29.45% 20.67% 20.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $272.0K $272.0K
YoY Change -88.19% -89.74% -89.74%
Total Long-Term Liabilities $200.0K $272.0K $272.0K
YoY Change -88.19% -89.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.315M $3.012M $3.012M
Total Long-Term Liabilities $200.0K $272.0K $272.0K
Total Liabilities $1.515M $3.284M $3.284M
YoY Change -57.42% -36.2% -36.2%
SHAREHOLDERS EQUITY
Retained Earnings $111.5M $109.2M
YoY Change 12.85% 15.43%
Common Stock $46.00K $30.00K
YoY Change -74.86% -79.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.75M $12.48M $12.48M
YoY Change
Total Liabilities & Shareholders Equity $15.26M $15.76M $15.76M
YoY Change 82.78% 25.98% 25.98%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$2.340M -$3.720M -$14.26M
YoY Change -44.35% -446.69% -46.42%
Depreciation, Depletion And Amortization $1.000K $2.000K $3.000K
YoY Change 0.0% 50.0%
Cash From Operating Activities -$3.526M -$3.306M -$13.36M
YoY Change -6.32% 8.22% -9.56%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$10.00K -$10.00K
YoY Change -81.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $14.40M
YoY Change 176.46%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.440M 1.714M 15.26M
YoY Change -5203.45% -409.39% -38.0%
NET CHANGE
Cash From Operating Activities -3.526M -3.306M -13.36M
Cash From Investing Activities -10.00K -10.00K
Cash From Financing Activities 4.440M 1.714M 15.26M
Net Change In Cash 914.0K -1.602M 1.888M
YoY Change -123.73% -55.61% -80.7%
FREE CASH FLOW
Cash From Operating Activities -$3.526M -$3.306M -$13.36M
Capital Expenditures $10.00K $10.00K
Free Cash Flow -$3.316M -$13.37M
YoY Change -9.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-33672
CY2022 dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
5800 Armada Drive, Suite 2A
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2022 dei City Area Code
CityAreaCode
858
CY2022 dei Local Phone Number
LocalPhoneNumber
704-4900
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2022 dei Trading Symbol
TradingSymbol
PALI
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
8100000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4503977
CY2022 dei Auditor Firm
AuditorFirmId
243
CY2022 dei Auditor Name
AuditorName
BDO USA, LLP
CY2022 dei Auditor Location
AuditorLocation
San Diego, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12383000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1011000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14733000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12512000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6547000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2430000
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11506000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
868000
CY2022Q4 us-gaap Assets
Assets
15763000
CY2021Q4 us-gaap Assets
Assets
12512000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1759000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1323000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
486000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
511000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
105000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2022Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
88000
CY2021Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
87000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3012000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2496000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
61000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2651000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
211000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Liabilities
Liabilities
3284000
CY2021Q4 us-gaap Liabilities
Liabilities
5147000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2944306
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2944306
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
284780
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
284780
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121637000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102002000
CY2022Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-109190000
CY2021Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-94642000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15763000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8764000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9307000
CY2022 us-gaap Restructuring Costs
RestructuringCosts
410000
CY2021 us-gaap Restructuring Costs
RestructuringCosts
0
CY2022 us-gaap Operating Expenses
OperatingExpenses
15721000
CY2021 us-gaap Operating Expenses
OperatingExpenses
41854000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-15721000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-41854000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2022 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
CY2021 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2426000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
23033000
CY2022 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
CY2021 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
CY2022 us-gaap Interest Expense
InterestExpense
13000
CY2021 us-gaap Interest Expense
InterestExpense
2398000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
158000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47000
CY2022 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2021 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
CY2022 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1110000
CY2021 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
3247000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1461000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15238000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.53
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-142.95
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.53
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-169.74
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
880311
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186195
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
880311
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186958
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14548000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26616000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14548000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31735000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1032000
CY2022 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
4956000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1891000
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1184000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28728000
CY2021 pali Stock Acquired During Period Value
StockAcquiredDuringPeriodValue
2000
CY2021 pali Adjustments To Additional Paid In Capital Equity Warrant Put Rights Activated Upon Merger
AdjustmentsToAdditionalPaidInCapitalEquityWarrantPutRightsActivatedUponMerger
-51000
CY2021 pali Adjustments To Additional Paid In Capital Expiration Of Put Rights On Equity Classified Warrants
AdjustmentsToAdditionalPaidInCapitalExpirationOfPutRightsOnEquityClassifiedWarrants
26000
CY2021 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1689000
CY2021 pali Conversion Of Share Liability To Common Stock
ConversionOfShareLiabilityToCommonStock
33000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
CY2022 pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
0
CY2021 pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
-135000
CY2022 pali Noncash Lease Expense
NoncashLeaseExpense
164000
CY2021 pali Noncash Lease Expense
NoncashLeaseExpense
166000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2022 us-gaap Accretion Expense
AccretionExpense
0
CY2021 us-gaap Accretion Expense
AccretionExpense
2339000
CY2022 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2021 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
CY2022 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
CY2021 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2022 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1110000
CY2021 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
3247000
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2426000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
23033000
CY2022 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
CY2021 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1032000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1891000
CY2022 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
233000
CY2021 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
192000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-84000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1027000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1157000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
399000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2395000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-25000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1120000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-151000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-168000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13360000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14773000
CY2022 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2021 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3279000
CY2022 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0
CY2021 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
3333000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54000
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
790000
CY2021 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1433000
CY2022 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
CY2021 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1250000
CY2022 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
19900000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14401000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5209000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2274000
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
99000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
627000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
67000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
151000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15258000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24609000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1888000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9782000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12383000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
12000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
64000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
355000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
388000
CY2021 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
0
CY2022 pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
288000
CY2021 pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
0
CY2022 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1274000
CY2021 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1689000
CY2022 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
55000
CY2021 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
0
CY2022 pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
459000
CY2021 pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
0
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2022 pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets And Oher Noncurrent Asstes
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAsstes
784000
CY2021 pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets And Oher Noncurrent Asstes
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAsstes
772000
CY2022 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
1408000
CY2021 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
0
CY2022 pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
0
CY2021 pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
135000
CY2022 pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
0
CY2021 pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
1184000
CY2022 pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
0
CY2021 pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
28728000
CY2022 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9503000
CY2022 pali Assets Assumed1
AssetsAssumed1
0
CY2021 pali Assets Assumed1
AssetsAssumed1
2000
CY2022 pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
0
CY2021 pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
41000
CY2022 pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
0
CY2021 pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
51000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
109200000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12400000
CY2021 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
0
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to clinical trial accruals and its derivative financial instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
114000
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accounts, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span></p>
CY2022Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
184000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2022 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-288000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14548000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26616000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
880311
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186195
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.53
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-142.95
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14260000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2022 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2021 us-gaap Dilutive Securities
DilutiveSecurities
-5119000
CY2022 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-288000
CY2021 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
0
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14548000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31735000
CY2022 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
880311
CY2021 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
186195
CY2022 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2021 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
763
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
880311
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186958
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.53
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-169.74
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1099459
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
182779
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1011000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11506000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
868000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2021Q4 us-gaap Assets
Assets
12512000
CY2021Q2 pali Number Of Directors
NumberOfDirectors
8
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
581000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
540000
CY2022Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
1438000
CY2021Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
150000
CY2022Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
157000
CY2021Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
215000
CY2022Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
54000
CY2021Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
78000
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
114000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
28000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1011000
CY2022 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
1400000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
69000
CY2021Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
195000
CY2022Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
184000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2022Q4 pali Accrued Director Stipends
AccruedDirectorStipends
141000
CY2021Q4 pali Accrued Director Stipends
AccruedDirectorStipends
110000
CY2022Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
180000
CY2021Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
682000
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
868000
CY2022Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2021Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
0
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
868000
CY2021Q3 us-gaap Warrants And Rights Outstanding Measurement Input
WarrantsAndRightsOutstandingMeasurementInput
3900000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1055672
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
143602
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
805202
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.38
CY2021Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
143602
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
294.71
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y5M12D
CY2022 pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
2396551
CY2022 pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
4.80
CY2022 pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P3Y14D
CY2022 pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
1482684
CY2022 pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
12.94
CY2022 pali Class Of Warrant Or Right Exercised During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageRemainingContractualLife
P2Y5M26D
CY2022 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
1797
CY2022 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
3879.49
CY2022Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
1055672
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
26.48
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P3Y3M25D
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
40.32
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
116.00
CY2022 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
CY2021 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y7M17D
CY2022 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0230
CY2021 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0125
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7366
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7432
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
39048
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
363.99
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
15852
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
40.32
CY2022 pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y2M26D
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
11242
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
110.43
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
43658
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
311.74
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
43658
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
311.74
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
31129
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
411.00
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M2D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.15
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
83.79
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
1000000.0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
1200000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
20000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
400000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1032000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1891000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
500000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y11M15D
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000.0
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2022 pali Milestone Payments
MilestonePayments
0
CY2021 pali Milestone Payments
MilestonePayments
0
CY2022 pali License Issue Fee
LicenseIssueFee
10000
CY2022 us-gaap Royalty Expense
RoyaltyExpense
1900000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
133000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
136000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
93000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
362000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
46000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
316000
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
7549
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
172.50
CY2022Q4 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-08-26
CY2022Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
141250
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
110000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2995000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5589000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1040000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1309000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
0
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
0
CY2022 pali Income Tax Reconciliation Nondeductible Expense Warrants
IncomeTaxReconciliationNondeductibleExpenseWarrants
-276000
CY2021 pali Income Tax Reconciliation Nondeductible Expense Warrants
IncomeTaxReconciliationNondeductibleExpenseWarrants
-3609000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
60000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
106000
CY2022 pali Income Tax Reconciliation Non Deductible In Process Research And Development Expense
IncomeTaxReconciliationNonDeductibleInProcessResearchAndDevelopmentExpense
0
CY2021 pali Income Tax Reconciliation Non Deductible In Process Research And Development Expense
IncomeTaxReconciliationNonDeductibleInProcessResearchAndDevelopmentExpense
5828000
CY2022 us-gaap Income Tax Reconciliation Minority Interest Income Expense
IncomeTaxReconciliationMinorityInterestIncomeExpense
0
CY2021 us-gaap Income Tax Reconciliation Minority Interest Income Expense
IncomeTaxReconciliationMinorityInterestIncomeExpense
-479000
CY2022 pali Income Tax Reconciliation Other Non Deductible Expenses
IncomeTaxReconciliationOtherNonDeductibleExpenses
71000
CY2021 pali Income Tax Reconciliation Other Non Deductible Expenses
IncomeTaxReconciliationOtherNonDeductibleExpenses
327000
CY2022 pali Income Tax Reconciliation Nondeductible Expense Expiration Of Tax Attributes
IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
484000
CY2021 pali Income Tax Reconciliation Nondeductible Expense Expiration Of Tax Attributes
IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
330000
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-157000
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-413000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3853000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3664000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
186000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 pali Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
91000
CY2021Q4 pali Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
59000
CY2022Q4 pali Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
192000
CY2021Q4 pali Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
206000
CY2022Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
0
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
1000
CY2022Q4 pali Deferred Tax Assets Lease Accounting
DeferredTaxAssetsLeaseAccounting
87000
CY2021Q4 pali Deferred Tax Assets Lease Accounting
DeferredTaxAssetsLeaseAccounting
29000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22681000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20904000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1955000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1737000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1912000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
0
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26918000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22936000
CY2022Q4 pali Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
83000
CY2021Q4 pali Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
28000
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
160000
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
86000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
243000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
114000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
26675000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
22822000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26675000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22822000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2022 pali Uncertain Income Tax Positions
UncertainIncomeTaxPositions
0
CY2021 pali Uncertain Income Tax Positions
UncertainIncomeTaxPositions
0
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1200000

Files In Submission

Name View Source Status
0000950170-23-009226-index-headers.html Edgar Link pending
0000950170-23-009226-index.html Edgar Link pending
0000950170-23-009226.txt Edgar Link pending
0000950170-23-009226-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img60072444_0.jpg Edgar Link pending
img60072444_1.jpg Edgar Link pending
img60072444_2.jpg Edgar Link pending
img60072444_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20221231.htm Edgar Link pending
pali-20221231.xsd Edgar Link pending
pali-ex10_23.htm Edgar Link pending
pali-ex10_35.htm Edgar Link pending
pali-ex10_36.htm Edgar Link pending
pali-ex19_1.htm Edgar Link pending
pali-ex21_1.htm Edgar Link pending
pali-ex23_1.htm Edgar Link pending
pali-ex23_2.htm Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
pali-20221231_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pali-20221231_cal.xml Edgar Link unprocessable
pali-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pali-20221231_def.xml Edgar Link unprocessable
pali-20221231_pre.xml Edgar Link unprocessable